Core Viewpoint - The proposed sale of Two Harbors Investment Corp. to UWM Holdings Corporation is under investigation to assess whether the transaction adequately values the company and the process leading to it is appropriate [1]. Group 1: Transaction Details - Shareholders of Two Harbors will receive 2.3328 shares of UWM Class A Common Stock for each share of Two Harbors they own as part of the proposed transaction [1]. Group 2: Legal Investigation - Kahn Swick & Foti, LLC is investigating the proposed sale to determine if the consideration undervalues Two Harbors Investment Corp. [1]. - The law firm is inviting shareholders who believe the transaction undervalues the company to discuss their legal rights regarding the proposed sale [2].

This ETF tracks companies advancing artificial intelligence and big data, offering targeted exposure to a rapidly evolving tech segment.What happenedAccording to an SEC filing dated January 23, 2026, Intelligence Driven Advisers, LLC reported initiating a new position in Global X Funds - Global X Artificial Intelligence & Technology ETF (AIQ +0.11%), acquiring 153,047 shares.The estimated value of the purchase was $7.78 million, calculated using the average share price during the filing quarter. The stake's ...

Company Performance - Medpace's stock closed at $588.05, down 3.01%, underperforming the S&P 500's gain of 0.03% on the same day [1] - Over the past month, Medpace's stock has increased by 6.02%, outperforming the Medical sector's slight loss of 0.01% and the S&P 500's gain of 0.6% [1] Upcoming Earnings - Medpace is set to release its earnings report on February 9, 2026, with an expected EPS of $4.18, reflecting a 13.9% increase year-over-year [2] - Revenue is anticipated to reach $681.17 million, indicating a 26.94% rise compared to the same quarter last year [2] Annual Estimates - For the annual period, Zacks Consensus Estimates project earnings of $14.8 per share and revenue of $2.5 billion, representing increases of 17.18% and no change, respectively, from the previous year [3] - Recent revisions to analyst forecasts for Medpace are crucial as they reflect short-term business trends and can indicate analysts' positive outlook on the company's health and profitability [3] Valuation Metrics - Medpace currently has a Forward P/E ratio of 36.47, which is significantly higher than the industry average Forward P/E of 16.37 [5] - The company has a PEG ratio of 2.04, compared to the industry average PEG ratio of 1.92 [6] Industry Ranking - The Medical Services industry, which includes Medpace, has a Zacks Industry Rank of 188, placing it in the bottom 24% of over 250 industries [6] - The Zacks Industry Rank evaluates the performance of industry groups based on the average Zacks Rank of individual stocks, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [7]

Company Performance - Pacific Biosciences of California (PACB) closed at $2.58, reflecting a decrease of -3.37% from the previous day's closing price, underperforming the S&P 500's daily gain of 0.03% [1] - Over the past month, PACB shares have increased by 42.02%, outperforming the Medical sector's slight loss of -0.01% and the S&P 500's gain of 0.6% [1] Earnings Expectations - Analysts anticipate that Pacific Biosciences will report earnings of -$0.19 per share, indicating a year-over-year growth of 5% [2] - For the entire fiscal year, the Zacks Consensus Estimates project earnings of -$1.89 per share and revenue of $0 million, representing changes of -127.71% and 0% from the prior year, respectively [2] Analyst Estimates - Recent changes to analyst estimates for Pacific Biosciences reflect shifting short-term business dynamics, with positive revisions indicating optimism about the business outlook [3] - The Zacks Rank system, which incorporates these estimate changes, provides an actionable rating system for investors [4] Zacks Rank and Industry Performance - The Zacks Rank system ranges from 1 (Strong Buy) to 5 (Strong Sell), with stocks rated 1 delivering an average annual return of +25% since 1988 [5] - Pacific Biosciences currently holds a Zacks Rank of 3 (Hold), with the consensus EPS projection remaining stagnant over the past 30 days [5] - The Medical - Instruments industry, part of the Medical sector, has a Zacks Industry Rank of 92, placing it in the top 38% of all industries [6]

Company Performance - Trip.com (TCOM) stock increased by 1.26% to $62.88, outperforming the S&P 500's daily gain of 0.03% [1] - Over the last month, TCOM shares decreased by 14.04%, while the Consumer Discretionary sector lost 3.17% and the S&P 500 gained 0.6% [1] Upcoming Financial Results - The upcoming EPS for Trip.com is projected at $0.72, indicating a 20.00% increase compared to the same quarter of the previous year [2] - Revenue is estimated to be $2.1 billion, reflecting a 20.05% increase compared to the same quarter of the previous year [2] Annual Forecast - Zacks Consensus Estimates forecast earnings of $6.38 per share and revenue of $8.71 billion for the year, showing changes of +77.72% and 0%, respectively, compared to the previous year [3] - Recent analyst estimate revisions indicate optimism regarding Trip.com's business and profitability [3] Analyst Ratings - The Zacks Rank system rates Trip.com as 1 (Strong Buy), with a historical average annual return of +25% for stocks rated 1 since 1988 [5] - The Zacks Consensus EPS estimate has remained stagnant over the past month [5] Valuation Metrics - Trip.com has a Forward P/E ratio of 14.64, which is lower than its industry's Forward P/E of 17.9, indicating a valuation discount [6] - The company holds a PEG ratio of 1.84, compared to the Leisure and Recreation Services industry's average PEG ratio of 1.47 [6] Industry Context - The Leisure and Recreation Services industry, part of the Consumer Discretionary sector, has a Zacks Industry Rank of 181, placing it in the bottom 27% of over 250 industries [7] - Research indicates that top-rated industries outperform the bottom half by a factor of 2 to 1 [7]

Company Performance - Ginkgo Bioworks Holdings, Inc. closed at $10.02, reflecting a -6.36% change from the previous day, underperforming the S&P 500's 0.03% gain [1] - Over the past month, shares of Ginkgo Bioworks have increased by 20.09%, outperforming the Medical sector's loss of 0.01% and the S&P 500's gain of 0.6% [1] Earnings Expectations - Analysts expect Ginkgo Bioworks to report earnings of -$1.8 per share, indicating a year-over-year growth of 1.1% [2] - The consensus estimate for revenue is $37 million, representing a 15.62% decrease compared to the same quarter of the previous year [2] Annual Forecast - For the entire year, Zacks Consensus Estimates predict earnings of -$5.94 per share and revenue of $173 million, showing changes of +42.66% and 0%, respectively, compared to the previous year [3] Analyst Sentiment - Recent changes to analyst estimates for Ginkgo Bioworks reflect evolving short-term business trends, with upward revisions indicating analysts' positive outlook on the company's operations [4] - The Zacks Rank system, which incorporates these estimate changes, currently ranks Ginkgo Bioworks as 3 (Hold) [6] Industry Context - Ginkgo Bioworks operates within the Medical - Biomedical and Genetics industry, which ranks in the top 36% of all industries according to the Zacks Industry Rank [7] - The Zacks Industry Rank assesses the strength of industry groups, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [7]

Company Performance - Akamai Technologies (AKAM) closed at $95.08, reflecting a -2.01% change from the previous day, underperforming the S&P 500's daily gain of 0.03% [1] - Prior to the latest trading session, shares had increased by 9.24%, surpassing the Computer and Technology sector's gain of 0.43% and the S&P 500's gain of 0.6% [1] Upcoming Financial Results - Akamai Technologies is set to announce its earnings on February 19, 2026, with projected EPS of $1.75, indicating a 5.42% increase year-over-year [2] - The consensus estimate for revenue is $1.08 billion, representing a 5.62% increase from the same quarter last year [2] Full Year Estimates - For the full year, earnings are projected at $7.03 per share, reflecting an 8.49% increase, while revenue is estimated at $4.19 billion, showing no change from the previous year [3] - Recent analyst estimate revisions suggest optimism regarding the company's business and profitability [3] Valuation Metrics - Akamai Technologies has a Forward P/E ratio of 13.39, which is lower than the industry average Forward P/E of 17.56, indicating a valuation discount [6] - The company has a PEG ratio of 2.25, compared to the Internet - Services industry's average PEG ratio of 1.8 [7] Industry Context - The Internet - Services industry, part of the Computer and Technology sector, holds a Zacks Industry Rank of 84, placing it in the top 35% of over 250 industries [7] - The Zacks Rank system, which evaluates stocks based on estimate changes, has a strong track record, with stocks rated 1 producing an average annual return of +25% since 1988 [5][4]

Company Performance - Rocket Lab Corporation (RKLB) stock increased by 1.05% to $88.90, outperforming the S&P 500's daily gain of 0.03% [1] - Over the last month, the company's shares have risen by 13.99%, significantly exceeding the Aerospace sector's gain of 4.86% and the S&P 500's gain of 0.6% [1] Earnings Projections - The upcoming earnings disclosure is projected to show an earnings per share (EPS) of -$0.05, which reflects a 50% increase from the same quarter last year [2] - Revenue is estimated to be $177.9 million, representing a 34.38% increase from the prior-year quarter [2] Full-Year Estimates - The full-year Zacks Consensus Estimates predict earnings of -$0.2 per share and revenue of $600.01 million, indicating year-over-year changes of +47.37% for earnings and 0% for revenue [3] - Recent changes to analyst estimates suggest a favorable outlook on the company's business health and profitability [3] Zacks Rank and Industry Performance - The Zacks Rank system, which evaluates estimate changes, currently assigns Rocket Lab Corporation a rank of 3 (Hold) [5] - The Aerospace - Defense Equipment industry ranks in the top 20% of all industries, with a current Zacks Industry Rank of 49 [6]

Record Date Payment Date Dividend Per Share Ordinary Taxable Dividend Return of Capital Capital Gain Unrecaptured Sec. 1250 Capital Gain (2) Section 199A Dividend 3/5/2025 3/17/2025 (1) $0.6625 $0.3455 $0.3170 $0.0000 $0.0000 $0.3455 5/5/2025 5/17/2025 $0.4500 $0.2347 $0.2153 $0.0000 $0.0000 $0.2347 8/13/2025 8/25/2025 $0.4500 $0.2347 $0.2153 $0.0000 $0.0000 $0.2347 11/7/2025 11/20/2025 $0.4500 $0.2347 $0.2153 $0.0000 $0.0000 $0.23 ...

Core Viewpoint - The article presents a cautious perspective on the investment potential of United States Antimony (UAMY), highlighting its rapid rise over the past year and suggesting a need for a more measured analysis of its future prospects [1]. Company Analysis - United States Antimony (UAMY) has experienced significant growth in the past 12 months, indicating a potentially lucrative investment opportunity [1]. - The author emphasizes the importance of rigorous standards in investment decisions, reflecting a disciplined approach to evaluating UAMY [1]. Sector Insights - The author has a strong background in the tech sector, particularly in SaaS and cloud businesses, but has recently expanded interest into the energy and minerals sectors, which are seen as offering substantial growth opportunities [1]. - The energy and minerals sectors are characterized by active developments and frequent news updates, making them engaging areas for research and investment [1].